Project Grant R01HL175371
Award Date
9/1/24
Completion Date
5/31/28
Dollars Obligated
$627K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
William Penn Annex West, PA 19107, USA
Similar Awards
This $773,446.00 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to better understand the early matricellular events in the injured lung and mechanisms critical for stabilizing the provisional matrix. The primary awardee, The Washington University, is leading this effort to identify targetable pathways for treating acute lung injury (ALI)/acute respiratory distress syndrome (ARDS)....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,063,324 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Tulane University. The grant, awarded on June 5, 2025, will support research to investigate the metabolic requirements and survival mechanisms of lung and nasal tissue-resident memory CD4+ T cells, and their interactions with lung fibroblasts, to enhance the understanding of pulmonary host defenses against respiratory pathogens. The research...
This federal Project Grant award, totaling $583,233.00 and issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to investigate the role of circulating osteopontin and innate immune cell CD44 in remote lung inflammation following acute kidney injury. The primary objectives are to: 1) determine which osteopontin domains and thrombin cleavage are required to induce remote lung inflammation, 2)...
This Project Grant award, valued at $605,678.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The study, conducted by the University of South Alabama, aims to explore the concept that a "base oxidation and repair activated chromatin restructuring" (BRACR)...
The federal Project Grant award R01HL174789, totaling $657,368.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research at The Washington University in St. Louis to decipher molecular pathways controlling post-transcriptional regulation and degradation of microRNAs (miRNAs), which play a critical role in hematopoietic development. The researchers will utilize human pluripotent stem cell...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support research focused on investigating short inhibitory RNAs (siRNAs) to modulate megakaryocyte and platelet function. The key objectives of this $552,413 award, with a performance period from April 1, 2025 to January 31, 2029, are to: 1) investigate in vivo siRNA-mediated knockdown of the P2Y12 receptor in megakaryocytes...
This federal Project Grant award, valued at $313,632.00 and provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a 5-year research project led by Dr. Joseph Cooley at National Jewish Health in Denver, Colorado. The project aims to investigate how interleukin-6 (IL-6) promotes resistance to apoptosis (programmed cell death) in lung fibroblasts, and to explore therapeutic strategies targeting the IL-6-BCL-2...
This $805,845 four-year federal Project Grant award (R01HL175948) from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of a novel Lung Precision Drug Delivery System (LPDDS). The goal is to create a targeted therapeutic approach that can actively transport anti-fibrotic agents directly into lung tissue to comprehensively block the activation and differentiation of myofibroblasts, a key...
This federal Project Grant award for $684,814, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine the mechanism by which tissue-resident lymphocytes (TRLs) suppress alveolar type 2 (AT2) stem cells in emphysema, a subtype of chronic obstructive pulmonary disease (COPD). The research aims to investigate how lung stromal factors modify TRL accumulation in response to viral infections and...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $277,610 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University. The grant titled "Determining the Role of TP53 Regulation in Alveolar Epithelial Transitional Cell State, and the Contribution of Alveolar Epithelial Transitional Cell State to Pulmonary Fibrosis" aims to uncover the mechanisms that regulate alveolar...